BC Extra | Sep 9, 2019
Clinical News

Sept. 9 Clinical Quick Takes: Translate to discontinue enzyme deficiency candidate; plus Janssen, Neurotrope, AMT and Cassava

Translate dropping enzyme deficiency program  Translate Bio Inc. (NASDAQ:TBIO) fell $0.73 to $9.25 in after-hours trade Monday after the company said that it is discontinuing development of MRT5201 for ornithine transcarbamylase deficiency based on preclinical...
Items per page:
1 - 1 of 1